Ariad Pharmaceuticals Inc. got a nice holiday gift from the FDA allowing for immediate resumption of sales of leukemia drug Iclusig (ponatinib), two months after it was suspended from the market, and pushing shares of the troubled biotech up 16.5 percent Friday.